cardiovascular disease
- Uric acid: role in cardiovascular disease and effects of losartan.
- Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce residual cardiovascular risk.
- Serum uric acid—a cardiovasular risk factor?
- Reduction in Cardiovascular Risk—Lower is Better through Dual Inhibition.
- The Essential Role of Cholesterol Absorption in Lipid Management.
- Dual Inhibition of Cholesterol Production and Absorption.
- Dual Inhibition of Cholesterol Production and Absorption.
- Evolving Concepts of Treating Atherosclerosis.
- Modifying Plasma Lipoprotein Levels for Therapeutic Benefit.
- Setting a New Standard in Cholesterol Management by Treating Both Cholesterol Absorption and Synthesis.
- Why Inhibiting Cholesterol Absorption and Production Is Today’s Treatment Standard.
- Diastolic Performance: Role of the Renin-Angiotensin-Aldosterone System.
- The Role of ACE Inhibitors in Preventing Myocardial Infarction: Potential Mechanisms and Clinical Implications.
- Recent Insights into the Beneficial Effects of ACE Inhibitors in Post-MI Patients.
- Managing hypertension in cardiology practice according to risk profile.
- Evidence-Based Medicine: Cardiovascular Strategies to Improve Outcome.
- Exploring the Potential of Angiotensin II Antagonists in Cardiovascular Management.
- Recent Insights into the Beneficial Effects of ACE Inhibitors in Post-MI Patients.
- The Role of ACE Inhibitors in Preventing Ischemic Events.
- The Role of AT1 Receptor Antagonists in Vascular and Renal Protection: An Evolving Paradigm.
- Transferring Evidence-Based Cardioprotection into Clinical Practice.
- Hypertension Treatment: First Do No Harm.
- Setting New Standards for the AII Antagonist Class.
- Innovations in the Management of the Hypertensive Patient in 2008.
- Angiotensin II antagonists –therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
- AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan.
- Role of Angiotensin II in Cardiovascular Disease – Therapeutic Implications of More Than a Century of Research.
- Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
- Do Angiotensin II Antagonists Provide Benefits Beyond Blood Pressure Reduction?
- Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
- Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management.
- The Lorenzini Foundation in a changing scenario of patient management.
- Bridging science and health policy in cardiovascular disease: focus on lipid management.
- Barriers to multiple risk factor management in cardiovascular disease.
